<DOC>
	<DOCNO>NCT00003088</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Giving drug different time combine one drug may kill tumor cell . It yet know chemotherapy regimen effective breast cancer . PURPOSE : Randomized phase III trial compare effectiveness chemotherapy consist either doxorubicin , cyclophosphamide , paclitaxel give different time combination chemotherapy consist doxorubicin plus cyclophosphamide follow paclitaxel treat woman stage II stage IIIA breast cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare sequential chemotherapy doxorubicin , paclitaxel cyclophosphamide combine doxorubicin cyclophosphamide follow paclitaxel disease free overall survival woman node positive stage II IIIA breast cancer . II . Determine whether increase dose density adjuvant chemotherapy improve disease free overall survival . III . Compare toxicity patient treat regimen . OUTLINE : This randomize study . Patients randomize one four arm ( sequential chemotherapy every 2 week vs every 3 week vs concurrent chemotherapy follow paclitaxel every 2 week vs every 3 week ) . All tumor remove either modified radical mastectomy segmental mastectomy plus axillary node dissection . Adjuvant chemotherapy start within 84 day follow last surgical procedure . Arm I : Patients receive sequential chemotherapy every 3 week . Doxorubicin IV administer every 3 week 4 dos . Paclitaxel IV administer 3 hour every 3 week 4 dos . Cyclophosphamide IV administer every 3 week 4 dos follow paclitaxel . Arm II : Patients receive sequential chemotherapy every 2 week . Doxorubicin IV administer every 2 week 4 dos . Paclitaxel IV administer 3 hour every 2 week 4 dos . Cyclophosphamide IV administer every 2 week 4 dos follow paclitaxel . Filgrastim ( G-CSF ) administer subcutaneous injection day 3-10 dose doxorubicin , paclitaxel , cyclophosphamide . Arm III : Patients receive combination chemotherapy every 3 week . Combination doxorubicin IV cyclophosphamide IV administer every 3 week 4 dos . Paclitaxel IV administer 3 hour every 3 week 4 dos follow combination chemotherapy . Arm IV : Patients receive combination chemotherapy every 2 week . Combination doxorubicin IV cyclophosphamide IV administer every 2 week 4 dos . Paclitaxel IV administer 3 hour every 2 week 4 dos follow combination chemotherapy . G-CSF administer subcutaneous injection day 3-10 dose doxorubicin/cyclophophamide dose paclitaxel . After completion chemotherapy , patient receive tamoxifen orally 5 year . Patients undergo radiotherapy 4-6 week completion chemotherapy . Patients follow every 6 month 5 year , annually death . PROJECTED ACCRUAL : A total 2,000 patient accrue study within 22 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>1 . Required Tumor Parameters 1.1 Patients operable , histologically confirm adenocarcinoma female breast positive lymph node . Node positivity may determine either axillary node dissection positive sentinel node find immunohistochemistry histology . This include patient one positive lymph node whose tumor T0 , T1 , 2 3 N1 , N2 , MO . Patients metaplastic carcinoma eligible . Bilateral disease exclude patient entry . 1.2 Tumors locally advanced diagnosis eligible . This leave investigator judgment . Patients tumor fix chest wall , peau d'orange skin change , skin ulceration , clinical inflammatory change ( T4 disease ) exclude study . Dermal lymphatic involvement note pathology without clinical inflammatory change exclude patient study . 1.3 Patients ERP/PgR status eligible . 2 . Prior treatment : 2.1 &lt; 84 day mastectomy within 84 day axillary dissection patient 's extensive breast surgery breast sparing procedure . 2.2 Surgical resection margin All tumor remove either modified radical mastectomy segmental mastectomy . Node dissection : patient may either axillary node dissection sentinel lymph node biopsy begin treatment protocol . Mastectomy : There evidence gross microscopic tumor surgical resection margin note final surgery pathology report patient modify radical mastectomy . Patients close margin ( tumor &lt; 1 mm margin ) eligible . Segmental mastectomy ( lumpectomy ) : Although clear margin preferable , DCIS LCIS surgical resection margin render patient undergone segmental mastectomy ineligible study . Invasive tumor final resection margin render patient ineligible . 2.3 No prior chemotherapy . 2.4 No prior radiation therapy malignancy . Patients receive radiation breast DCIS eligible . Patients segmental mastectomy treat radiotherapy accord standard procedure treat physician 's institution completion chemotherapy . Patients modify radical mastectomy may also receive radiotherapy discretion treat physician accord institutional guideline . 2.5 Patients may receive four week tamoxifen therapy malignancy still eligible study entry . Patients receive tamoxifen purpose chemoprevention ( e.g. , Breast Cancer Prevention Trial ) indication ( include previous breast cancer ) eligible . Tamoxifen therapy discontinue patient enrol study . 3 . Age &gt; 18 . There upper age limit enrollment study . 4 . Required initial laboratory data : Granulocyte count &gt; 1000/mm3 Platelet count &gt; 100,000/mm3 Bilirubin within upper limit normal</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
</DOC>